anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of medicine, and discloses a special solution for preventing skin lesion after chemotherapeutic drug exosmosis. Raw materials of the special solution include 50% magnesium sulfate, 2% lidocaine, dexamethasone, 5% sodium bicarbonate, anisodamine, vitamin B 12 and 0.9% saline solution. The raw materials are allocated proportionally according to different characteristics of each raw material; bottling the mixture respectively with 100ml in each bottle after even mixing; and the special solution is prepared after sealing, sterilization process and labeling. The special solution for preventing the skin lesion after the chemotherapeutic drug exosmosis has the advantages that the fading away of tissue edema is promoted, vessels are enabled to constrict so as to relieve the pain; vasospasm of patients can be eliminated, microcirculation can be improved, repair and regeneration of intestine epithelial cells and vascular endothelial cells of damaged skins are facilitated, cambium growth is accelerated; hair follicles, a sweat gland and subcutaneous tissues are repaired, chemotherapeutic drug absorption is reduced, medicine formation of a DNA compound can be prevented, toxic effects of exosmosis drugs are decreased, skin necrosis is prevented, and the skin is protected. According to the special solution, patients undergoing chemotherapy can receive the chemotherapy well, length of hospital stay is shortened, and pains and family burdens of the patients are reduced. The special solution has simple preparation, convenient operation, and low cost which is easy for the patients to accept. The total effective rate reaches 98% after clinical use on more than 150 chemotherapeutic exosmosis patients, and no special toxic or side effects appears.
Patients receive oral indinavir sulfate 350 mg/m\^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10\^6 injection; harvested autologous T cells (minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
Platelet aggregation can initiate thrombosis on ulcerated arterial plaques resulting in acute coronary syndrome (ACS). There is large variation in platelet aggregation between individuals. As the genetic message to the cell machinery is conveyed through its transcriptome, we hypothesize that much of the variability in platelet function can be explained by transcriptome changes including differences in gene or isoform expression, altered splicing events, or allele-specific expression. Moreover, aspirin modifies gene expression in several cells, but whether it also affects platelet transcriptome has not yet been studied. Our goal is to characterize the platelet transcriptome and identify genes that are up- or down-regulated after 4-week aspirin therapy. A major strength of our study is that it enrolls individuals from European Americans and African Americans and thus will have the ability to study similarities and differences between the two. The study will produce innovative comparative genomic/platelet phenotype data and will provide a potential pharmacogenomic and diagnostic template for the future discovery of novel antiplatelet regimens to prevent thrombosis-related cardiovascular disease events.
The invention discloses a Ganoderma Lucidum coffee comprising: 15-20 weight portions of a Ganoderma Lucidum substance made from Ganoderma Lucidum and Chinese medicines; 8-10 weight portions of coffee. The Ganoderma Lucidum substance comprises Cortex Eucommiae, Rhizoma Polygonati, Radix Codonopsis and Radix Achyranthis Bidentatae. The invention provides a Ganoderma Lucidum coffee which is made by special preparation process using the materials including Ganoderma Lucidum and other Chinese medicines. The above mixtures will then be cooked with coffee. Such Ganoderma Lucidum coffee has a rich aroma of coffee and a positive health effect on our body sourced from Ganoderma Lucidum and the above Chinese medicines. The Chinese medicines such as Cortex Eucommiae, Rhizoma Polygonati, Radix Codonopsis and Radix Achyranthis Bidentatae will dilute the bitter taste of Ganoderma Lucidum and coffee. As such, people enjoy drinking the Ganoderma Lucidum coffee regardless the bitter taste of Ganoderma Lucidum and coffee themselves and will tend to accept for becoming their daily drinking habit. On the other hand, the above Chinese medicines together with Ganoderma Lucidum contain rich plant polysaccharides and they can upgrade the nutrient contents of the Ganoderma Lucidum coffee. If it is for long term use, it will strengthen the health of user and increase the energy level.
A total of 26 adolescent subjects with Major Depressive Disorder(MDD), ages 12 to 20, will be consented and join this project at UCLA. For analytic purposes, we will define an "enrolled" subject as one who has completed the single-blind lead-in week and one week of double-blind treatment, and the three EEG recordings at these visits, as any subject who leaves the project prior to that point cannot contribute useful data to testing our hypotheses.

Subjects who enroll in this project will receive 1 week of single-blind placebo lead-in, followed by 8 weeks of double-blind randomized treatment either with fluoxetine (FLX), a Selective Serotonin Reuptake Inhibitor (SSRI) with FDA approval for use in this age group, or with placebo. Brain activity will be assessed with Qualitative EEG (QEEG) recording at pretreatment baseline, after lead-in, and at 1, 2, 4, and 8 weeks of treatment to expand the evidence base on the neurophysiology of treatment response in adolescents. Subjects will be assessed for symptom change, adverse events, and suicidality at each visit. Functional measures related to treatment will be assessed at baseline and at weeks 4 and 8. Subjects and the staff who interact with them will be blinded to QEEG biomarker values during the project.
Participants will receive two oral doses (morning and evening) of placebo matching miricorilant 1350 mg (9 X 150 mg) after a meal on Day 1 (Regimen C1). After a minimum 7-day washout, participants will receive placebo matching miricorilant 750 mg (5 X 150 mg) after breakfast for 14 days and placebo matching miricorilant 600 mg (4 X 150 mg) in the evening after a meal for 13 days (Regimen C2). Cohort 3 treatments will be randomized and blinded.
Developing modified dietary fibers that maintain prebiotic benefits without significantly affecting meal taste is of high importance in the midst of the obesity pandemic. These benefits include regulating the composition of gut microbiota, increasing feelings of fullness, and improving human metabolic parameters. This study investigated the use of a resistant dextrin (RD) derived from potato starch, which possesses prebiotic properties, as a potential additive in vegetable-fruit preparations that aid weight loss and improve health markers in overweight children. HPLC was employed to examine metabolites like lactic acid, short-chain fatty acids (SCFAs; formic, acetic, propionic, butyric, and valeric acids), and branched-chain fatty acids (BCFAs; isobutyric and isovaleric acids). The activities of α-glucosidase, β-glucosidase, α-galactosidase, β-galactosidase, and β-glucuronidase enzymes in fecal samples were measured using spectrophotometric analysis at a wavelength of 400 nm. Incorporating the RD into vegetable-fruit preparations yielded favorable outcomes in terms of increased concentrations of the tested metabolites (SCFAs and BCFAs) and enhanced fecal enzyme activities after 6 months of consuming the preparations. Furthermore, these effects were found to last for an extended period of 3 months even after discontinuing the treatment. The study has shown that including RD into vegetable-fruit preparations enhances the metabolic parameters of obese and overweight children, hence providing a strong rationale for the widespread usage of these preparations in the industry.
This study has been designed as a prospective, randomized and single-blind trial. Local ethics committee of Ataturk University has approved the study (B.30.2.ATA.0.01.00/142). After obtaining the patients' written informed consents, we will include a total number of 94 patients (47 patients for each group). The inclusion criteria of the study was considered as age between 18-80, American Society of Anesthesiologists (ASA) status I-III, eligible for regional anesthesia, and unilateral shoulder surgery. The patients who have clotting disorder, contra-indication for regional anesthesia, infection on the injection site, chronic opioid usage, previous same side shoulder surgery, severe Chronic obstructive pulmonary disease (COPD) , diaphragmatic paralysis, BMI 35 or over will be excluded. A computer-generated randomization program will be used to allocate the patient into two groups. Interscalene brachial plexus block group will be named as Group ISB (n=47) and cervical ESP block group will be named as Group cESP (n=47). The assessor of the outcomes will be blinded to the study groups of the patients. Both ISB block and cervical ESP block will be performed under ultrasound guidance in the block room preoperatively.
The invention discloses a traditional Chinese medicine composition for treating osteoporosis, a preparation method and applications thereof. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 5 to 10 parts of root of okra, 14 to 18 parts of psoralea corylifolia, and 7 to 16 parts of dried orange peel. The preparation method comprises the following steps: burning okra root by strong fire until okra root becomes grey, taking out okra root from strong fire, grinding okra root into powder, sieving the powder by a 250-mesh sieve to obtain fine powder; adding dried orange peel into a pot, scorching the dried orange peel by slow fire, taking out dried orange peel from the pot, cooling, grinding, sieving the powder by a 80-120 mesh sieve to obtain coarse powder; mixing psoralea corylifolia with the coarse powder, extracting the mixture by hot water, merging three water extracts, filtering the water extract to obtain filtrate, condensing the filtrate to obtain thick paste, mixing the thick paste with fine powder, and making the mixture into capsules. The formula is simple. The raw materials (okra root, psoralea corylifolia, and dried orange peel) are cheap and easily-available. The raw materials cooperate with each other to generate functions of invigorating the spleen, tonifying the kidney, regulating qi, activating blood, freeing channels, activating collaterals, eliminating swelling, relieving pain, and strengthening muscles and bones. The traditional Chinese medicine composition can treat both the root and symptoms of osteoporosis and thus is worthy to promote and use.
Charts will be prescreened for diagnosis or suspicion of osteoarthritis of the knee by the study staff. Those charts identified will be flagged for possible inclusion in the study. The receptionist will give the prospective subject a copy of the consent to read while they are in the waiting room. Once they are taken back to the room, the investigator will review the study with them. If they are agreeable, they will sign the consent and a copy will be given to them and a copy will be scanned into the Electronic Medical Record (EMR). The investigator will then notify the unblinded investigator, who will randomize the subject and prepare the medication in a blinded fashion. The subject will receive either ketorolac 30 mg, triamcinolone 40 mg, or a combination of the two medications as a one-time injection into the affected knee joint/s. The subject will be asked to complete a survey prior to receiving the injection, and again at 1 week, 6 weeks, and 12 weeks post injection. If necessary, an additional survey will be completed at 24 weeks post injection.
1333570 Enzyme-containing detergents AJINOMOTO CO Inc 30 Dec 1970 [30 Dec 1969] 61726/70 Heading C5D A detergent composition comprises an N-acyl amino acid having an acyl group of 6-20 carbon atoms, or a salt or ester thereof, together with at least one enzyme. The N-acylamino acid is a surfactant and may comprise the whole or part of the surfactant component of the composition. It is a stabilizer for the enzyme in neutral or alkaline media, is non-irritating to the skin and has antibacterial properties. Salts are alkali metal, ammonium and aliphatic amine salts and salts with inorganic and organic acids. Esters are alkyl esters, e.g. methyl, octyl and lauryl esters. The amino acid component may be acidic (e.g. glutamic acid, adipic acid and aspartic acid); basic (e.g. lysine, arginine, ornithine and histidine); or neutral (e.g. glycine, alanine, valine, serine and taurine). The fatty acid residue includes residues from coconut oil-, tallow-, hydrogenated tallow- and soyabeanfatty acids. Other detergents (e.g. sodium ndodecylbenzene sulphonate, sodium lauryl sulphate, lauryl alcohol ether sulphate, and alkylolamide of coconut oil fatty acids); builders and conventional additives for specific purposes, e.g. shampoos, bar soaps, automatic dish wash detergents and household detergents, may be present.
Worsening of Seizures: When used in patients in whom several different types of seizure disorders coexist, clonazepam may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and clonazepam may produce absence status.

Laboratory Testing During Long-Term Therapy: Periodic blood counts and liver function tests are advisable during long-term therapy with clonazepam.

Risks of Abrupt Withdrawal: The abrupt withdrawal of clonazepam, particularly in those patients on long-term, high-dose therapy, may precipitate status epilepticus. Therefore, when discontinuing clonazepam, gradual withdrawal is essential. While clonazepam is being gradually withdrawn, the simultaneous substitution of another anticonvulsant may be indicated.

Caution in Renally Impaired Patients: Metabolites of clonazepam are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function.

Hypersalivation: Clonazepam may produce an increase in salivation. This should be considered before giving the drug to patients who have difficulty handling secretions. Because of this and the possibility of respiratory depression, clonazepam should be used with caution in patients with chronic respiratory diseases.
One of the factors that contributes to suicide risk is what is known as a "suicidal belief system." This belief system is made up of several cognitions, including hopelessness, thwarted belongingness, perceived burdensomeness, unlovability, unbearability, and unsolvability. These cognitions have all been associated with suicide risk among military personnel. Modification of these cognitions may reduce suicidal thoughts and behaviors. The study team has developed a brief mobile intervention entitled the Mobile Intervention for Suicidal Thoughts (MIST) that uses evidence-based interpretation bias modification techniques to reduce these suicide cognitions. The goal of this project is to is to conduct a pilot trial of the MIST intervention to evaluate whether it is feasible an acceptable as an adjunct treatment for Veterans with suicidal ideation.

The investigators will conduct a pilot randomized controlled trial (RCT), in which 50 Veterans with suicidal ideation will be randomized to either MIST plus Treatment as Usual and Safety Planning versus Treatment as Usual and Safety Planning. The central hypothesis is that Veterans will find MIST acceptable and will be willing to use it to reduce their suicidal thoughts.
Risperidone may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.2% (6/2607) of risperidone-treated patients in Phase 2 and 3 studies in adults with schizophrenia. The risk of orthostatic hypotension and syncope may be minimized by limiting the initial dose to 2 mg total (either once daily or 1 mg twice daily) in normal adults and 0.5 mg twice daily in the elderly and patients with renal or hepatic impairment [see Dosage and Administration (2.1, 2.4)] . 

Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if hypotension occurs. Risperidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension, e.g., dehydration and hypovolemia, and in the elderly and patients with renal or hepatic impairment. Monitoring of orthostatic vital signs should be considered if hypotension occurs. Clinically significant hypotension has been observed with concomitant use of risperidone and antihypertensive medication.
Techniques are disclosed for determining a risk assessment corresponding to a level of risk that a user of a service organization has or will develop a condition. The techniques include receiving user data associated with a user record of a user. The techniques further include inputting the user data into a trained prediction model of a user condition prediction system. The user data may include a plurality of data points, weighted relative to each other, that respectively correspond to one of a plurality of categories. The techniques further include determining, by the trained prediction model, a risk assessment of a user condition based on the user data. The risk assessment may then be provided to a user device of a user service agent for use coordinating user service.
Vedolizumab, a monoclonal antibody targeting integrin α4β7, is used to inhibit recruitment of inflammatory cells. This drug is always used as second-line treatment for patients with moderate-to-severe active stage Crohn's Disease who fail to respond to conventional treatments such as tumor necrosis factor-α inhibitor. This study uses Vedolizumab as control group to illustrate the efficacy and safety of Upadacitinib in second-line treatment for Crohn's Disease. Entyvio is the marketed drugs for clinical use, should be given intra-arterially in week 0, 2, 6 and every subsequent 8 weeks.
The present invention provides a compound having a structure shown in formula (I), an isomer thereof, a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising said compound. Provided is an application of the present compound and pharmaceutical composition thereof in preparation of a drug for preventing and/or treating a cancer. The present compound has a good ex-vivo cytotoxic activity and a good in-vivo antitumor effect. The preparation method for the compound is easy and raw materials are easy to obtain. Therefore, the present compound has a wide medicinal prospect. (I)
Bumex is a loop diuretic with a rapid onset and short duration of action. Pharmacological and clinical studies have shown that 1 mg Bumex has a diuretic potency equivalent to approximately 40 mg furosemide. The major site of Bumex action is the ascending limb of the loop of Henle.

The mode of action has been determined through various clearance studies in both humans and experimental animals. Bumex inhibits sodium reabsorption in the ascending limb of the loop of Henle, as shown by marked reduction of free-water clearance (CH2O) during hydration and tubular free-water reabsorption (TCH2O) during hydropenia. Reabsorption of chloride in the ascending limb is also blocked by Bumex, and Bumex is somewhat more chloruretic than natriuretic.

Potassium excretion is also increased by Bumex, in a dose-related fashion. 

Bumex may have an additional action in the proximal tubule. Since phosphate reabsorption takes place largely in the proximal tubule, phosphaturia during Bumex induced diuresis is indicative of this additional action. This is further supported by the reduction in the renal clearance of Bumex by probenecid, associated with diminution in the natriuretic response. This proximal tubular activity does not seem to be related to an inhibition of carbonic anhydrase. Bumex does not appear to have a noticeable action on the distal tubule. 

Bumex decreases uric acid excretion and increases serum uric acid. Following oral administration of Bumex the onset of diuresis occurs in 30 to 60 minutes. Peak activity is reached between 1 and 2 hours. At usual doses (1 mg to 2 mg) diuresis is largely complete within 4 hours; with higher doses, the diuretic action lasts for 4 to 6 hours. Diuresis starts within minutes following an intravenous injection and reaches maximum levels within 15 to 30 minutes.

Several pharmacokinetic studies have shown that bumetanide, administered orally or parenterally, is eliminated rapidly in humans, with a half-life of between 1 and 1½ hours. Plasma protein-binding is in the range of 94% to 96%.

Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Urinary and biliary metabolites identified in this study were formed by oxidation of the N-butyl side chain. Biliary excretion of Bumex amounted to only 2% of the administered dose.
Participants will receive sham stimulation. Participants and/or study partners (if applicable) will keep a manual log of daily operation, including the time of day used, whether the participant felt drowsy or, was able to complete the entire session, or if the participant was unable to complete the therapy that day. Finally, study staff will contact participants monthly every 2 weeks to ensure compliance, assess adverse events, and log concomitant medications.
In the virtual reality intervention, participants will complete the scheduled educational module five times in the week of the intervention. This VR is assisting users in using immersive reality to reduce pain, learning cognitive and behavior self-coping skills and retraining the pain pathways. There are several sessions, which will be delivered using an all-in-one head-mounted display. Each session varies in duration approximately from 3 to 15 minutes.
The lack of accessible therapies amenable for application in the home setting is a major obstacle for treating patients who suffer from lower-extremity peripheral artery disease (PAD). The investigators will determine whether unsupervised, home-based leg heat therapy (HT) improves walking performance compared to a sham intervention. Leg HT will be applied using water-circulating trousers coupled with a water pump and a water heater. Patients will be randomized into one of two groups: those receiving HT (n=53) or those receiving a sham treatment (n=53).The water heater and pump given to participants in the HT group will be adjusted to circulate water at 42ºC through the trousers. In the sham group, water at 33ºC will be circulated through the trousers. Participants will be asked to apply the therapy daily for 90 min for 3 consecutive months. Outcomes will be assessed at baseline, at the completion of the intervention (end of week 12) and at a follow-up visit, 12 weeks after the end of the intervention (week 24). The primary study outcome is the change in 6-minute walk distance between baseline and the 12-week follow up. Secondary outcomes include changes in the short physical performance battery score, which combines performance in walking speed, standing balance, and repeated chair rises, changes in handgrip strength, perceived quality of life (measured by the Walking Impairment Questionnaire and Short-Form (SF)-36 Questionnaire), calf muscle strength (measured using a calf ergometer), size (measured by magnetic resonance imaging) and bioenergetics (assessed using phosphorus-31 magnetic resonance spectroscopy), and physical activity (measured by accelerometer).